EASE Appoints Dr. Kanyinsola Oyeyinka as CEO, Driving Medical Equipment-as-a-Service in Africa
23.4.2025 09:03:00 CEST | Business Wire | Press Release
EASE Holdings BV has promoted Dr. Kanyinsola Oyeyinka to Chief Executive Officer to succeed Imraan Soomra, who will, effective May 1, take on a new role as Non-Executive Director of EASE South Africa, the group’s most advanced unit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423749021/en/
Dr. Kanyinsola Oyeyinka speaks at a healthcare event in Rustenburg, South Africa, in January 2025, where she shared insights from EASE’s growing footprint across the continent.
The appointments come as EASE accelerates the rollout of its Equipment-as-a-Service model, which enables clinics and hospitals to access state-of-the-art PET-CT and MRI scanners, surgical robots, and other high-value machines without significant capital outlay by paying on a per-scan or per-event basis to align their costs with revenue. EASE South Africa is set to lead the rapid expansion of the service after announcing an agreement this month for Standard Bank to provide debt funding for future installations.
Dr. Oyeyinka, who previously served in the UK National Health Service as a medical doctor and had senior roles at the World Bank and the Nigeria Sovereign Investment Authority, has worked across the full healthcare value chain from frontline clinical care to building sustainable diagnostic and oncology platforms and shaping systems-level health reforms. During her three years as Senior Vice President at EASE, Dr. Oyeyinka has led operations in South Africa and Ghana, and driven strategic cross-border scaling with a clear vision for delivering world-class medical technology across Africa and other emerging markets.
“It is thanks to the coordinated leadership between Imraan and Kanyinsola that EASE has built a solid foundation, secured commercial debt funding, and grown our installed base through trusted partnerships,” said Frans van Schaik, Chairman of EASE. “Through her vast experience and commitment, Kanyinsola brings continuity, clarity and passion in taking over the mantle from Imraan, who remains central to driving the biggest component of the EASE network in South Africa.”
EASE’s equipment-as-a-service model has been proven with several installations in recent months. Commissioning of a PET-CT scanner at the Precision Nuclear Oncology and Theranostics facility (PNOAT) in Rustenburg, South Africa, earlier this year followed the deployment of a da Vinci surgical robot in KwaZulu-Natal, South Africa, and an advanced MRI diagnostic imaging system in Akwatia, Ghana.
Without the burden of heavy upfront equipment costs, a longstanding barrier for many healthcare centres in accessing the latest technology, capital is freed up for priorities such as increasing hospital beds and nursing staff. A first-of-its-kind for Africa, this initiative is set to change the healthcare landscape for many hospitals and clinics.
“EASE is more than a business; it’s a platform to rethink how healthcare infrastructure is delivered, financed, and sustained,” Dr. Oyeyinka said. “I’m proud to lead an organisation that is empowering hospitals and clinics to be more deliberate in their use of limited resources to better serve patients.”
The culmination of long-term strategic planning, EASE’s leadership transition ensures that the company enters its next chapter with both stability and momentum. The role draws on the full spectrum of Dr. Oyeyinka’s experience, having served as a doctor, a health financing consultant, a healthcare investment adviser and a member of EASE’s management team.
“Dr. Oyeyinka truly embodies our mission and has been central to our journey to this point,” said Imraan Soomra. “I look forward to continuing our work together with Dr. Oyeyinka at the helm developing EASE in its next international growth phase.”
About EASE
Equipment-as-a-Service (EASE®) is a pay-per-use program that provides businesses and organisations with cost-effective access to state-of-the-art healthcare equipment – and maintenance, training and support – with terms that match their circumstances and business needs. EASE South Africa is a subsidiary of EASE Holdings BV which is headquartered in the Netherlands and has operations in multiple African countries. To find out more about EASE, visit https://www.easeglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250423749021/en/
Contacts
Media Contacts:
EASE Holdings
Cydney Bell
press@easeglobal.com
+254 791 854841
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom